(+)-JQ1

Name: (+)-JQ1
Brand: Selleck Chemicals
SKU: S7110
Rating: 5 (281 reviews)

For research use only.

Catalog No.S7110

281 publications

CAS No. 1268524-70-4

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family. (+)-JQ1 suppresses cell proliferation via inducing autophagy. (+)-JQ1 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes.

Selleck's (+)-JQ1 has been cited by 281 publications

Cell, 2021, S0092-8674(21)00354-8

PubMed: 33811809 ( click the link to review the publication )

Cell, 2020, 182(4):992-1008.e21

PubMed: 32710817 ( click the link to review the publication )

Nat Genet, 2020, 52(4):408-417

PubMed: 32203462 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2018, 34(2):271-285.e7

PubMed: 30107177 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):512-526

PubMed: 29533787 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Nat Med, 2017, 23(4):493-500

PubMed: 28263307 ( click the link to review the publication )

Nat Med, 2017, 23(9):1046-1054

PubMed: 28805821 ( click the link to review the publication )

Cancer Discov, 2017, 7(3):302-321

PubMed: 28108460 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Gastroenterology, 2014, 147(5):1119-33

PubMed: 25127677 ( click the link to review the publication )

Biomaterials, 2021, 275:120958

PubMed: 34130142 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108750

PubMed: 33596424 ( click the link to review the publication )

Elife, 2021, 10e63810

PubMed: 33835029 ( click the link to review the publication )

Oncogene, 2021, 40(22):3799-3814

PubMed: 33958721 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):106

PubMed: 33741018 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1376

PubMed: 33803654 ( click the link to review the publication )

PLoS Pathog, 2021, 17(1):e1009091

PubMed: 33411730 ( click the link to review the publication )

Mol Cancer Ther, 2021, 20(4):691-703

PubMed: 33509905 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:682561

PubMed: 34179011 ( click the link to review the publication )

J Virol, 2021, JVI.02124-20

PubMed: 33762408 ( click the link to review the publication )

Life Sci, 2021, S0024-3205(21)00467-7

PubMed: 33891939 ( click the link to review the publication )

J Antibiot (Tokyo), 2021, 10.1038/s41429-021-00433-2

PubMed: 34163027 ( click the link to review the publication )
Tissue Cell, 2021, 72:101555

PubMed: 33957539 ( click the link to review the publication )

Am J Cancer Res, 2021, 11(2):530-545

PubMed: 33575085 ( click the link to review the publication )

EBioMedicine, 2021, 65:103241

PubMed: 33647768 ( click the link to review the publication )

NPJ Breast Cancer, 2021, 7(1):51

PubMed: 33980863 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108749

PubMed: 33596420 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 16;7(7):1902926

PubMed: 32274304 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202021450

PubMed: 33310900 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2246.2020

PubMed: 33109736 ( click the link to review the publication )

Cancer Res, 2020, canres.1030.2020

PubMed: 32934021 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):261

PubMed: 33239043 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2668

PubMed: 32962010 ( click the link to review the publication )

Cell Death Dis, 2020, 17;11(4):239

PubMed: 32303673 ( click the link to review the publication )

Br J Cancer, 2020, 4

PubMed: 32362655 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2020, 6;19:109-123

PubMed: 31837602 ( click the link to review the publication )

J Mol Cell Biol, 2020, 11;12(5):359-371

PubMed: 31565729 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(5):4547-4557

PubMed: 32163373 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(1):397-415

PubMed: 31901895 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(10):9240-9259

PubMed: 32392533 ( click the link to review the publication )

Carcinogenesis, 2020, 41(9):1282-1293

PubMed: 31826234 ( click the link to review the publication )

Epigenetics, 2020, 22:1-13

PubMed: 32164487 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 10.1007/s13402-020-00497-6

PubMed: 32166583 ( click the link to review the publication )
Cancer Sci, 2020, 111(10):3503-3515

PubMed: 32726482 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):523-535

PubMed: 32195024 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(1):148-163

PubMed: 32064158 ( click the link to review the publication )

Oncogenesis, 2020, 9(3):33

PubMed: 32157097 ( click the link to review the publication )

ACS Chem Biol, 2020, 17;15(4):895-903

PubMed: 32176478 ( click the link to review the publication )

J Immunol, 2020, 204(5):1242-1254

PubMed: 31988180 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:565820

PubMed: 33134168 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15901

PubMed: 32954665 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(2):1650-1657

PubMed: 31821686 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(18)E6873

PubMed: 32961679 ( click the link to review the publication )

Sci Rep, 2020, 10(1):15837

PubMed: 32985581 ( click the link to review the publication )

Sci Rep, 2020, 10(1):19723

PubMed: 33184327 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00570-8

PubMed: 33311600 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Int J Biol Macromol, 2020, 164:3204-3220

PubMed: 32860796 ( click the link to review the publication )

Front Pharmacol, 2020, 8;11:618

PubMed: 32457617 ( click the link to review the publication )

Int J Oncol, 2020, 56(6):1429-1441

PubMed: 32236593 ( click the link to review the publication )

Exp Cell Res, 2020, 24:112034

PubMed: 32339606 ( click the link to review the publication )

Med Sci Monit, 2020, 8;26:e923411

PubMed: 32266878 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0160

PubMed: 32703768 ( click the link to review the publication )

Cancer Cell, 2020, 37(4):584-598

PubMed: 32220301 ( click the link to review the publication )
Front Oncol, 2020, 9:1471

PubMed: 31993368 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01393-x

PubMed: 32747750 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002

PubMed: 32175692 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33222

PubMed: 32683685 ( click the link to review the publication )

Cancer Lett, 2020, 491:50-59

PubMed: 32735909 ( click the link to review the publication )

Inflamm Regen, 2020, 40:25

PubMed: 33072227 ( click the link to review the publication )

Blood Adv, 2020, 4(20):5062-5077

PubMed: 33080008 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):673

PubMed: 32826850 ( click the link to review the publication )

Sci Transl Med, 2019, 11(497)

PubMed: 31217338 ( click the link to review the publication )

Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )

Nat Commun, 2019, 10(1):335

PubMed: 30659195 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3201

PubMed: 31324758 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(2)

PubMed: 30610113 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Genome Res, 2019, 29(10):1659-1672

PubMed: 31515287 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(6):2220-2225

PubMed: 30659143 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2415-2425

PubMed: 30885979 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Theranostics, 2019, 9(13):3840-3852

PubMed: 31281517 ( click the link to review the publication )

Cancer Res, 2019, 79(19):4869-4881

PubMed: 31311807 ( click the link to review the publication )

Cancer Res, 2019, 79(18):4599-4611

PubMed: 31358529 ( click the link to review the publication )

Cell Rep, 2019, 28(13):3497-3509

PubMed: 31553917 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )
Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):73

PubMed: 31288832 ( click the link to review the publication )

Redox Biol, 2019, 24:101195

PubMed: 31004990 ( click the link to review the publication )

Oncogene, 2019, 38(47):7249-7265

PubMed: 31420604 ( click the link to review the publication )

Cancer Lett, 2019, 442:373-382

PubMed: 30419347 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):383

PubMed: 31470872 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):557

PubMed: 31324754 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):324

PubMed: 30975979 ( click the link to review the publication )

Cell Death Dis, 2019, 10(11):815

PubMed: 31653826 ( click the link to review the publication )

Addict Biol, 2019, 10.1111/adb.12808

PubMed: 31364211 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2111-2123

PubMed: 31467179 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2019, 10.1016/j.jtcvs.2019.06.115

PubMed: 31564537 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13305

PubMed: 31527644 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17369

PubMed: 31758083 ( click the link to review the publication )

Biomed Pharmacother, 2019, 114:108793

PubMed: 30921702 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(14):4748-4758

PubMed: 31731295 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(3):481-488

PubMed: 31530390 ( click the link to review the publication )

J Oral Pathol Med, 2019, 10.1111/jop.12906

PubMed: 31177574 ( click the link to review the publication )

SLAS Discov, 2019, 24(2):142-157

PubMed: 30204533 ( click the link to review the publication )
Mol Med Rep, 2019, 19(1):499-507

PubMed: 30483785 ( click the link to review the publication )

Oncol Lett, 2019, 18(3):2340-2347

PubMed: 31452730 ( click the link to review the publication )

Can J Physiol Pharmacol, 2019, 97(11):1028-1034

PubMed: 31330113 ( click the link to review the publication )

Nucleic Acids Res, 2019, gkz1139

PubMed: 31822909 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0682-7

PubMed: 31862959 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Journal of Oral Pathology & Medicine, 2019, 10.1111/jop.12906

PubMed: 无 ( click the link to review the publication )

JScholarship, 2019, None

PubMed: None ( click the link to review the publication )

Mol Cell, 2018, 72(2):341-354

PubMed: 30270106 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1532

PubMed: 29670088 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3815

PubMed: 30232459 ( click the link to review the publication )

EMBO J, 2018, 37(5)

PubMed: 29440228 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(40):E9317-E9324

PubMed: 30181285 ( click the link to review the publication )

J Am Soc Nephrol, 2018, 29(6):1690-1705

PubMed: 29739813 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Cell Rep, 2018, 22(8):2016-2025

PubMed: 29466730 ( click the link to review the publication )

Cell Rep, 2018, 24(7):1722-1729

PubMed: 30110629 ( click the link to review the publication )

Oncogene, 2018, 37(28):3763-3777

PubMed: 29636547 ( click the link to review the publication )

J Med Chem, 2018, 61(2):453-461

PubMed: 28378579 ( click the link to review the publication )

Cancers (Basel), 2018, 10(1)

PubMed: 29346274 ( click the link to review the publication )

Clin Epigenetics, 2018, 10:01

PubMed: 29312470 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29988031 ( click the link to review the publication )
Cells, 2018, 7(10)

PubMed: 30304769 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e419

PubMed: 29303513 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 50(2):798-809

PubMed: 30308485 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2796-2810

PubMed: 30242092 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Gynecol Oncol, 2018, 149(3):575-584

PubMed: 29567272 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

J Virol, 2018, 92(2)

PubMed: 29118124 ( click the link to review the publication )

Epigenetics Chromatin, 2018, 11(1):30

PubMed: 29884215 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Sci Rep, 2018, 8(1):998

PubMed: 29343723 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5808-5820

PubMed: 29475942 ( click the link to review the publication )

Int J Oncol, 2018, 53(6):2503-2517

PubMed: 30272279 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2018, 59(1):132-143

PubMed: 29332125 ( click the link to review the publication )

Bioorg Med Chem, 2018, 26(1):25-36

PubMed: 29170024 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190682

PubMed: 29298347 ( click the link to review the publication )

Int J Stem Cells, 2018, 11(1):131-140

PubMed: 29699387 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 499(3):531-537

PubMed: 29596834 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(4):931-940

PubMed: 28750570 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(5):1248-1251

PubMed: 28885069 ( click the link to review the publication )

Oncotarget, 2018, 9(41):26491-26506

PubMed: 29899872 ( click the link to review the publication )
Oncotarget, 2018, 9(71):33482-33499

PubMed: 30323893 ( click the link to review the publication )

Blood Adv, 2018, 2(23):3428-3442

PubMed: 30504235 ( click the link to review the publication )

Oncotarget, 2018, 9(11):9907-9924

PubMed: 29515779 ( click the link to review the publication )

Oncotarget, 2018, 9(83):35408-35421

PubMed: 30459933 ( click the link to review the publication )

JCI Insight, 2018, 3(19)

PubMed: 30282829 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8:14802

PubMed: 28378740 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(14):8403-8410

PubMed: 28854735 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(15):4462-4472

PubMed: 28270499 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(36):E7554-E7563

PubMed: 28784769 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(27):E5352-E5361

PubMed: 28630312 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(43):E9135-E9144

PubMed: 29073110 ( click the link to review the publication )

Genes Dev, 2017, 31(12):1212-1227

PubMed: 28724615 ( click the link to review the publication )

Cancer Res, 2017, 77(20):5564-5575

PubMed: 28819026 ( click the link to review the publication )

J Am Soc Nephrol, 2017, 28(2):504-519

PubMed: 27436852 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cell Rep, 2017, 21(10):2796-2812

PubMed: 29212027 ( click the link to review the publication )

Haematologica, 2017, 102(10):1776-1784

PubMed: 28751557 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(4):371-379

PubMed: 26388239 ( click the link to review the publication )

Sci Signal, 2017, 10(508)

PubMed: 29208683 ( click the link to review the publication )
J Med Chem, 2017, 60(24):9990-10012

PubMed: 29172540 ( click the link to review the publication )

J Med Chem, 2017, 60(14):6289-6304

PubMed: 28650658 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1436-1449

PubMed: 28923910 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1739-1750

PubMed: 28572168 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1155-1165

PubMed: 28246302 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2017, 1863(12):3001-3015

PubMed: 28844955 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):35-44

PubMed: 27707886 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8027

PubMed: 28808321 ( click the link to review the publication )

Skelet Muscle, 2017, 7(1):16

PubMed: 28870238 ( click the link to review the publication )

J Chem Inf Model, 2017, 57(7):1677-1690

PubMed: 28636361 ( click the link to review the publication )

Org Biomol Chem, 2017, 15(44):9352-9361

PubMed: 29087414 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(22):4384-4394

PubMed: 28471170 ( click the link to review the publication )

Cell Biosci, 2017, 7:56

PubMed: 29118968 ( click the link to review the publication )

Molecules, 2017, 23(1)

PubMed: 29295560 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2581-2593

PubMed: 28553123 ( click the link to review the publication )

J Gen Virol, 2017, 98(4):799-809

PubMed: 28113052 ( click the link to review the publication )

Biol Res, 2017, 50(1):19

PubMed: 28545522 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37140-37153

PubMed: 28415755 ( click the link to review the publication )
Oncotarget, 2017, 9(9):8334-8349

PubMed: 29492199 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98068-98083

PubMed: 29228674 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51402-51415

PubMed: 28881656 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98471-98481

PubMed: 29228703 ( click the link to review the publication )

J Chem Inf Model, 2017, 57(7):1677-1690

PubMed: 28636361 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19478-19490

PubMed: 28061448 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16646

PubMed: 29192216 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(7):504-10

PubMed: 27159579 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2448

PubMed: 27401245 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(42):11865-11870

PubMed: 27679845 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(31):E4558-66

PubMed: 27432991 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3319-31

PubMed: 26988986 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(17):4440-51

PubMed: 27103402 ( click the link to review the publication )

Cancer Res, 2016, 76(5):1204-13

PubMed: 26837760 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1313-9

PubMed: 26759243 ( click the link to review the publication )

Cell Rep, 2016, 16(5):1366-1378

PubMed: 27425608 ( click the link to review the publication )

Cell Rep, 2016, 15(2):310-22

PubMed: 27050521 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):134

PubMed: 27903272 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005950

PubMed: 27764245 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )
PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Cancer Discov, 2016, 6(6):612-29

PubMed: 27099234 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0750

PubMed: 26939702 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1217-26

PubMed: 26983878 ( click the link to review the publication )

J Virol, 2016, 90(18):8059-73

PubMed: 27356901 ( click the link to review the publication )

J Biol Chem, 2016, 291(41):21694-21702

PubMed: 27576686 ( click the link to review the publication )

Oncol Rep, 2016, 36(4):1989-96

PubMed: 27573714 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 469(3):679-85

PubMed: 26707881 ( click the link to review the publication )

Oncotarget, 2016, 6(7):5134-46

PubMed: 25762617 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6576-92

PubMed: 26536665 ( click the link to review the publication )

Sci Rep, 2016, 6:23770

PubMed: 27044328 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79637-79653

PubMed: 27793034 ( click the link to review the publication )

Blood, 2015, 126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

Nat Commun, 2015, 6:10091

PubMed: 26631872 ( click the link to review the publication )

Sci Adv, 2015, 1(8):e1500221

PubMed: 26601252 ( click the link to review the publication )

Cancer Res, 2015, 75(21):4548-59

PubMed: 26483207 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:121

PubMed: 26515759 ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )

Arch Toxicol, 2015, 89(2):179-91

PubMed: 25559776 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1034416

PubMed: 25941994 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Sci Rep, 2015, 5:10120

PubMed: 25944566 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )
Exp Ther Med, 2015, 10(6):2319-2324

PubMed: 26668635 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Nat Chem Biol, 2014, 10(4):305-12

PubMed: 24584101 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(26):E2721-30

PubMed: 24979794 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(26):9503-8

PubMed: 24979803 ( click the link to review the publication )

Cancer Res, 2014, 74(23):7090-102

PubMed: 25277525 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Cancer Res, 2014, 74(21):5999-6009

PubMed: 25164011 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(11):2896-910

PubMed: 25106422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Drug Metab Dispos, 2013, 41(10):1725-31

PubMed: 23918665 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63563

PubMed: 23704919 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Handb Exp Pharmacol, 2011, 206:1-12

PubMed: 21879443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Target Protein Ligand Inhibitors

Biological Activity

Description

Features

(+)-JQ1 is more effective than (-)-JQ1.

Targets

BRD4 (2) ^[1] (Cell-free assay)	BRD4 (1) ^[1] (Cell-free assay)
33 nM	77 nM

In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. ^[1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. ^[2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. ^[3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
K1	M2niTWNmdGxiVnnhZoltcXS7IFHzd4F6	MWiyOVAwPTByL{GwNFAhdk1?	NHfLWIMzPC92OD:3NkBp	MWPEUXNQ	M1fwRolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjdyN{i4NUc,OjZ5MEe4PFE9N2F-
BCPAP	NIrZUYhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVPJO5VwOjVyL{WwNE8yODByIH7N	NYrzT3p1OjRxNEivO\|IhcA>?	M4rDbWROW09?	MUnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	NFrrZWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkewO\|g5OSd-Mk[3NFc5QDF:L3G+
K1	NUHqbZQ4S2WubDDDfYNt\SCDc4PhfS=>	MV2yOVAwPTByL{GwNFAhdk1?	MXe3NkBp	MmLhSG1UVw>?	NV3mWW5{[XK{ZYP0d{Bk\WyuIHP5Z4xmKGG2IFewM2cyKHCqYYPl	NGjxOGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkewO\|g5OSd-Mk[3NFc5QDF:L3G+
BCPAP	M3fIW2NmdGxiQ4njcIUhSXO\|YYm=	MV6yOVAwPTByL{GwNFAhdk1?	M3G4bFczKGh?	NYTOfHhKTE2VTx?=	NHq5RoRienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS\|EheGijc3W=	NVnQNldkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3NFc5QDFpPkK2O\|A4QDhzPD;hQi=>
Hep3B	M3TJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXKwMVExKM7:TR?=	M1rIbFUh\A>?	Mmi5SG1UVw>?	M2P1TGlEPTB;MD6wPEDPxE1?	M4TWXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUe1NVY4Lz5{NkW3OVE3PzxxYU6=
HCCLM3	Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHufllNOC1zMDFOwG0>	Mmq2OUBl	MWPEUXNQ	NIDXOohKSzVyPUCuNVQh\|ryP	M2TLT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUe1NVY4Lz5{NkW3OVE3PzxxYU6=
HuH7	NWnDW3hZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TQN\|AuOTBizszN	MWO1JIQ>	NGe0dJdFVVOR	MVXJR\|UxRTBwMkGg{txO	M3\STFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUe1NVY4Lz5{NkW3OVE3PzxxYU6=
HepG2	MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fFPFAuOTBizszN	MmX3OUBl	NHThS4dFVVOR	MYLJR\|UxRTBwM{Sg{txO	MlziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3N{WxOlcoRjJ4NUe1NVY4RC:jPh?=
SMMC7721	NGOxVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7EbYplOC1zMDFOwG0>	M{fIe\|Uh\A>?	NVrhV4E1TE2VTx?=	NXfVfZhsUUN3ME2wMlQyKM7:TR?=	M17od\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUe1NVY4Lz5{NkW3OVE3PzxxYU6=
BEL7402	NVfzOW1oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHxVJh6OC1zMDFOwG0>	NELIeoQ2KGR?	MnjvSG1UVw>?	NYPqXlhpUUN3ME2wMlQ4KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV5NUG2O{c,OjZ3N{WxOlc9N2F-
MHCC97H	NVTWVVQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFKxXpUxNTFyIN88US=>	M3;KOlUh\A>?	MmeySG1UVw>?	M4POT2lEPTB;MD60NUDPxE1?	NWTo[JJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1O\|UyPjdpPkK2OVc2OTZ5PD;hQi=>
Hep3B	MV\D[YxtKEO7Y3zlJGF{e2G7	NI\KS5cxNjFxMD61M\|IvPSEQvF2=	MkW1OFghcA>?	MXfEUXNQ	M3fSSIxm[WS\|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV5NUG2O{c,OjZ3N{WxOlc9N2F-
HCCLM3	Mor4R4VtdCCFeXPs[UBCe3OjeR?=	MnnnNE4yNzBwNT:yMlUh\|ryP	Ml\sOFghcA>?	MVjEUXNQ	M17ZWoxm[WS\|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>?	NV3qdFduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1O\|UyPjdpPkK2OVc2OTZ5PD;hQi=>
Hep3B	MYfBdI9xfG:\|aYOgRZN{[Xl?	NUW5NodTOC5zL{CuOU8zNjVizszN	MkPSOFghcA>?	MVXEUXNQ	M4ewVoFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO\|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF?	MlXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3N{WxOlcoRjJ4NUe1NVY4RC:jPh?=
HCCLM3	NETZfYZCeG:ydH;zbZMhSXO\|YYm=	MWCwMlEwOC53L{KuOUDPxE1?	MUG0PEBp	NEjFT\|JFVVOR	MoL2ZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>?	NU\kbodERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1O\|UyPjdpPkK2OVc2OTZ5PD;hQi=>
A549	M3XXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXtT2YxNjFvMUCg{txO	M1y2RlczKGh?		NFfvT4NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NE\RZZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSxOVIzPSd-Mk[0NVUzOjV:L3G+
H157	NHXjbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVOwMlEuOTBizszN	NXrqdI1pPzJiaB?=		NIDVbpdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M1WxSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEG1NlI2Lz5{NkSxOVIzPTxxYU6=
H1299	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV2wMlEuOTBizszN	MmHrO\|IhcA>?		NHvRO21qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NY\NXFVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NVUzOjVpPkK2OFE2OjJ3PD;hQi=>
A549	MWTGeY5kfGmxbjDBd5NigQ>?	M1j2bVEwOi53L{Wg{txO	MkmwNVIhcA>?		MlPTxsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>?	NFK0XGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSxOVIzPSd-Mk[0NVUzOjV:L3G+
H1299	NVPyXmpiTnWwY4Tpc44hSXO\|YYm=	M1jxeFEwOi53L{Wg{txO	NFjScJUyOiCq		NI\6NVbDqHenYXvsfUBl\WO{ZXHz[YQhSmOuLUKgcIV3\Wy\|	NWflOXplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NVUzOjVpPkK2OFE2OjJ3PD;hQi=>
H157	NU\HepR[TnWwY4Tpc44hSXO\|YYm=	MXqxM\|IvPS93IN88US=>	MoDyNVIhcA>?		NGT3PINl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36=	M3PM[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEG1NlI2Lz5{NkSxOVIzPTxxYU6=
H1299	MnzMSpVv[3Srb36gRZN{[Xl?	M2TSOlEwOi53L{Wg{txO	MkO2NVIhcA>?		NUjabGEx\GWlcnXhd4VlKESUNDDlfJBz\XO\|aX;u	NUmwRphMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NVUzOjVpPkK2OFE2OjJ3PD;hQi=>
C8161	NXztXm04S2WubDDWbYFjcWyrdImgRZN{[Xl?	MWGwMVIh\|ryP	MWK0JIQ>	MYXEUXNQ	M17HNYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M4jY[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m3NlI{Lz5{NkO5O\|IzOzxxYU6=
Mel285	NF\MbmxE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M4LvSFAuOiEQvF2=	MXS0JIQ>	MlXhSG1UVw>?	MUfk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M{j0XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m3NlI{Lz5{NkO5O\|IzOzxxYU6=
Mel290	NVe3c5J2S2WubDDWbYFjcWyrdImgRZN{[Xl?	NYH4d2JXOC1{IN88US=>	MofFOEBl	NEjkVoJFVVOR	NEWwSoll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXrHe\|lERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVczOjNpPkK2N\|k4OjJ\|PD;hQi=>
92.1	MljoR4VtdCCYaXHibYxqfHliQYPzZZk>	MXywMVIh\|ryP	NFXUWpI1KGR?	MYnEUXNQ	NYfDU4d3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NXPEcm9PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVczOjNpPkK2N\|k4OjJ\|PD;hQi=>
Omm1.3	NYDlOFFKS2WubDDWbYFjcWyrdImgRZN{[Xl?	M1\QWVAuOiEQvF2=	M1\KW\|Qh\A>?	MXvEUXNQ	NHjlc2Jl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NE\NZpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|IzOyd-Mk[zPVczOjN:L3G+
Mel202	MnXzR4VtdCCYaXHibYxqfHliQYPzZZk>	MmrWNE0zKM7:TR?=	M2PUelQh\A>?	Ml24SG1UVw>?	M1GxXYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MnTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUeyNlMoRjJ4M{m3NlI{RC:jPh?=
Mel270	Mn:3R4VtdCCYaXHibYxqfHliQYPzZZk>	MUSwMVIh\|ryP	MkK5OEBl	M2XUbWROW09?	MWfk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NV;rWIFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVczOjNpPkK2N\|k4OjJ\|PD;hQi=>
Omm1	NHHpWVhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NFi2cHExNTJizszN	NI\tbnE1KGR?	M2q4b2ROW09?	M3PaXoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M{LVT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m3NlI{Lz5{NkO5O\|IzOzxxYU6=
92.1	NXe1UWdMSXCxcITvd4l{KEG\|c3H5	NV;UeGt2PTByIH7N	MoC4OFghcA>?	NEHHXINFVVOR	NFXJeYRqdmS3Y3XzJIFxd3C2b4Ppdy=>	NV3ncHZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVczOjNpPkK2N\|k4OjJ\|PD;hQi=>
Omm1.3	NUfN[2JJSXCxcITvd4l{KEG\|c3H5	NHnpXo82ODBibl2=	NEDwTpU1QCCq	M1;pZ2ROW09?	MoTlbY5lfWOnczDhdI9xfG:\|aYO=	NF\NUlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|IzOyd-Mk[zPVczOjN:L3G+
92.1	MojtR4VtdCCFeXPs[UBCe3OjeR?=	NH7LO242ODBibl2=	NHn1TpMzPC92OD:3NkBp	NFToN5FFVVOR	NGfCVZdqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?=	NFHFWnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|IzOyd-Mk[zPVczOjN:L3G+
Omm1.3	NV;iZYliS2WubDDDfYNt\SCDc4PhfS=>	NFPzemM2ODBibl2=	NEPEVFIzPC92OD:3NkBp	MWLEUXNQ	NV\UfHZ4cW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC=	NYrYSVZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVczOjNpPkK2N\|k4OjJ\|PD;hQi=>
A549	NWXDdYhUTnWwY4Tpc44hSXO\|YYm=	M{jRfVExOC92MECvNVAxOCCwTR?=	M1j6VVI1KGh?		NWO2SHh5fXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?=	NGDEOmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKxNlE6QSd-Mk[yNVIyQTl:L3G+
MCF-7	NVH1fIpYTnWwY4Tpc44hSXO\|YYm=	NVT1TlBFOTByL{SwNE8yODByIH7N	M1jsXVI1KGh?		MnW4eZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>?	M1HwdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkGyNVk6Lz5{NkKxNlE6QTxxYU6=
HEK293	NXLWNpFJTnWwY4Tpc44hSXO\|YYm=	NYSwZYY6OTByL{SwNE8yODByIH7N	MVqyOEBp		NYGxPJdYfXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?=	NUDnXGR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNVIyQTlpPkK2NlEzOTl7PD;hQi=>
858	MkDYR4VtdCCYaXHibYxqfHliQYPzZZk>	NWLrZWRNOC1zIN88US=>	M33JZ\|Uh\A>?	NFnscVBFVVOR	NYDGUJVy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NFXpNWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKwOlM{Oyd-Mk[yNFY{OzN:L3G+
DDR2L63V	M17ndmNmdGxiVnnhZoltcXS7IFHzd4F6	M{nZS\|AuOSEQvF2=	MnjsOUBl	NWXxbpZlTE2VTx?=	NWLNUJBL\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NVfZ[3NORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFY{OzNpPkK2NlA3OzN\|PD;hQi=>
BE(2)-C	MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MWOxJO69VQ>?	NV3FSlduOS12IHS=		Mlrs[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB4N{S2OEc,OjZyNke0OlQ9N2F-
IMR-32	NULyfIF3S2WubDDWbYFjcWyrdImgRZN{[Xl?	M2Ht[FEh\|ryP	MkS2NU01KGR?		M2XmNYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB4N{S2OEc,OjZyNke0OlQ9N2F-
JF	MniyR4VtdCCYaXHibYxqfHliQYPzZZk>	M4LWc\|Eh\|ryP	MWmxMVQh\A>?		NIrmV25l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	MkPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNke0OlQoRjJ4ME[3OFY1RC:jPh?=
BE(2)-M17	NEnCT2xE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M{fSTFEh\|ryP	NXjsU4QxOS12IHS=		MmP2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>	NHWwPFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC2O\|Q3PCd-Mk[wOlc1PjR:L3G+
SK-N-SH	NXTIboRQS2WubDDWbYFjcWyrdImgRZN{[Xl?	MUOxJO69VQ>?	MYKxMVQh\A>?		Mlro[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>	NG[1NWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC2O\|Q3PCd-Mk[wOlc1PjR:L3G+
SK-N-DZ	MlfsR4VtdCCYaXHibYxqfHliQYPzZZk>	MV2xJO69VQ>?	MmT2NU01KGR?		NHTnc5ll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	MkHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNke0OlQoRjJ4ME[3OFY1RC:jPh?=
HMC-1.1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NID4XXI2NTVyMECgcm0>	Mm[yOFghcA>?	M2fhNWROW09?	NYDaTnNxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M1H5eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1N\|A{Lz5{NkC1OVMxOzxxYU6=
HMC-1.2	NWLWNFVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DUdlUuPTByMDDuUS=>	MYe0PEBp	NXvW[ZprTE2VTx?=	M{DSbolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NVTpe4F[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU{ODNpPkK2NFU2OzB\|PD;hQi=>
ROSA KIT WT	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXO1MVUxODBibl2=	NHnrNYc1QCCq	MmfLSG1UVw>?	MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUOwN{c,OjZyNUWzNFM9N2F-
ROSA KIT D816V	M1\CTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTEOU02ODByIH7N	NWqwSXQ3PDhiaB?=	MljKSG1UVw>?	MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUOwN{c,OjZyNUWzNFM9N2F-
HMC-1.1	NFLVeWlCeG:ydH;zbZMhSXO\|YYm=	MlzENlAxNTVyMECgcm0>	NF7IOpY1QCCq	MX;EUXNQ	Mnr6bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M{fkNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1N\|A{Lz5{NkC1OVMxOzxxYU6=
HMC-1.2	MoX0RZBweHSxc3nzJGF{e2G7	NFPCVFAzODBvNUCwNEBvVQ>?	NInrb\|c1QCCq	M4jHS2ROW09?	NHOwXmVqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NYr4UmVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU{ODNpPkK2NFU2OzB\|PD;hQi=>
ROSA KIT WT	MoTsRZBweHSxc3nzJGF{e2G7	NUToPJRMOjByLUWwNFAhdk1?	MoLKOFghcA>?	M3X6OmROW09?	M2P6WYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUOwN{c,OjZyNUWzNFM9N2F-
ROSA KIT D816V	NX7jOHFJSXCxcITvd4l{KEG\|c3H5	NUT0[oZLOjByLUWwNFAhdk1?	MmLHOFghcA>?	NYToZopuTE2VTx?=	MWfpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MorrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUWzNFMoRjJ4MEW1N\|A{RC:jPh?=
494H	NUHiPYtDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUC3NkBp	NHjReGFFVVOR	NHHRTVZKSzVyPUCuNVIzyrFyLkCwOEDPxE1?	M4DCVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
493H	NEjxZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{XKVVczKGh?	NEW2eo1FVVOR	NIXlc2xKSzVyPUCuNFQ4yrFyLkCwPUDPxE1?	M2D1eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
716H	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml3JO\|IhcA>?	NYf3[WM1TE2VTx?=	NX65S5Y5UUN3ME2wMlIyOsLzMD6wN\|Qh\|ryP	MnTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
148I	M3;Gdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX;uUVY{PzJiaB?=	Mmm2SG1UVw>?	NHPxZ\|dKSzVyPUCuNlg1yrFyLkCzOUDPxE1?	M3Hsb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
98Sc	M{K1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXLjdlBZPzJiaB?=	M{fYXWROW09?	MYrJR\|UxRTBwMUG1xtExNjByNDFOwG0>	M4TaXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
89R	Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXG1V4dYPzJiaB?=	NITSRplFVVOR	M3[yXGlEPTB;MD6xNlbDuTBwMECzJO69VQ>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
494L	MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4riWlczKGh?	NHq4XlRFVVOR	NXnsSmxxUUN3ME2wMlMyP8LzMD6wNVIh\|ryP	NV;HO5p7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
493L	NG[yb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{HJblczKGh?	M1\TNGROW09?	NUXuT3lLUUN3ME2wMlA2OMLzMD6wNVEh\|ryP	M2f0e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
148L	NYfMTFJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGnWbII4OiCq	NHnxNWFFVVOR	NVLEU4pDUUN3ME2wMlE1PsLzMD6wNVch\|ryP	NELhN\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
98L	NUPLdZFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M371TVczKGh?	M{j3b2ROW09?	MXHJR\|UxRTBwM{C5xtExNjB{OTFOwG0>	M{mzZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
OS17	NELtfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXO3NkBp	NGXRXopFVVOR	NGTZVGRKSzVyPUCuNFc6yrFyLkCwN{DPxE1?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
OS9	M3iw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYDydnYxPzJiaB?=	MonzSG1UVw>?	MV\JR\|UxRTBwNEC2xtExNjB{ODFOwG0>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
MG63	M4WzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmXjO\|IhcA>?	MXrEUXNQ	M3fke2lEPTB;MD6xNVTDuTBwMEK1JO69VQ>?	MmHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
SAOS2	NHXIWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVnado9iPzJiaB?=	NVXiUYVzTE2VTx?=	NFvXbVZKSzVyPUCuNlE4yrFyLkCwN{DPxE1?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
U2OS	MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4\NcVczKGh?	NXvZOItMTE2VTx?=	MYrJR\|UxRTBwMUm4xtExNjByODFOwG0>	Mo\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
SJSA-1	NV20NolJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3HMNFczKGh?	M4LjbmROW09?	M37INGlEPTB;MD6xNFDDuTBwMEGwJO69VQ>?	Mn[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
494H	M{PJUWFxd3C2b4Ppd{BCe3OjeR?=	M3n6T\|AvOjVxMD61M\|EvOCEQvF2=	MnvKNlQhcA>?	MlvnSG1UVw>?	NVvSW29[cW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li	NEG3[II9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
148I	NIPyZ5RCeG:ydH;zbZMhSXO\|YYm=	MYOwMlI2NzBwNT:xMlAh\|ryP	NXPSSVExOjRiaB?=	MoDkSG1UVw>?	MojBbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
OS17	Ml7FRZBweHSxc3nzJGF{e2G7	NH;YS\|QxNjJ3L{CuOU8yNjBizszN	NVm3R4FnOjRiaB?=	NUfzU\|JGTE2VTx?=	NXfEclA3cW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li	MlXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
494H	M{HiNWFxd3C2b4Ppd{BCe3OjeR?=	NXGwNnFsOeLCid88US=>	MmrkOFghcA>?	MkX6SG1UVw>?	M1rs[Ilv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=>	Mnq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
148I	MULBdI9xfG:\|aYOgRZN{[Xl?	MX[x5qCK\|ryP	MXy0PEBp	M4P2bmROW09?	M3LOfYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=>	NVPIT3hwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
OS17	MlTPRZBweHSxc3nzJGF{e2G7	NHf3[Yoy6oDLzszN	MVi0PEBp	MXjEUXNQ	NHXH[HhqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IIPp[45q\mmlYX70cJk>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
MOLM13	NHv4b4lCeG:ydH;zbZMhSXO\|YYm=	M{j1RVI2OCCwTR?=	M33wTFQ5KGh?	NXvrXYY1TE2VTx?=	M{G4RYlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?=	MnL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUO4NlUoRjJ3MEWzPFI2RC:jPh?=
MV4-11	MkX4RZBweHSxc3nzJGF{e2G7	M{\oTVI2OCCwTR?=	MkDaOFghcA>?	NXv5S3Z[TE2VTx?=	NIDp[o9qdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m\|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK=	Ml3MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUO4NlUoRjJ3MEWzPFI2RC:jPh?=
MOLM13	NFrP[GZHfW6ldHnvckBCe3OjeR?=	NEDiZWEzPTBibl2=	M{nMPFI1KGh?	M1ize2ROW09?	NIjFfGhmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC=	NVv4eoRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVM5OjVpPkK1NFU{QDJ3PD;hQi=>
MV4-11	NF7BdZlHfW6ldHnvckBCe3OjeR?=	MonrNlUxKG6P	NYr6WZBOOjRiaB?=	NWP4d5pbTE2VTx?=	MXLlcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB?	NITyR3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1N\|gzPSd-MkWwOVM5OjV:L3G+
MOLM13	MWTBdI9xfG:\|aYOgRZN{[Xl?	NWHWPWhiOjVyIH7N	MonmOFghcA>?	MYLEUXNQ	NXfOSJN6cW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIDvcoF1cW6rYh?=	M{Xpd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWzPFI2Lz5{NUC1N\|gzPTxxYU6=
MV4-11	MlHjRZBweHSxc3nzJGF{e2G7	M4qwTlI2OCCwTR?=	NXvrTVNsPDhiaB?=	NGC4epBFVVOR	M2\Nc4lv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ?	MlLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUO4NlUoRjJ3MEWzPFI2RC:jPh?=
Hela	NGjrboRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MWWwMVUxOCCwTR?=	NVu3NZRWPzJiaB?=	MV7EUXNQ	MWHk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NFvpZ2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
HBL-1	NHv2fmdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MW[wMVUxOCCwTR?=	M4jwdlczKGh?	Mn7qSG1UVw>?	NXe1R2hs\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NUf5bXRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
HLY-1	NVHPZVdFS2WubDDWbYFjcWyrdImgRZN{[Xl?	NUXlVoVuOC13MECgcm0>	Mon5O\|IhcA>?	M{j2fmROW09?	NVrzfYhl\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	Mo[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEmyPVUoRjJ3MEC5Nlk2RC:jPh?=
OCI-Ly3	NY\2O5ZWS2WubDDWbYFjcWyrdImgRZN{[Xl?	MW[wMVUxOCCwTR?=	M1r4V\|czKGh?	NVPOfJF1TE2VTx?=	MWfk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
OCI-Ly10	MoTSR4VtdCCYaXHibYxqfHliQYPzZZk>	M3Tr[\|AuPTByIH7N	M2\ZVFczKGh?	NYm4ZZZMTE2VTx?=	MmrD[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NGXIXWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
SU-DHL-4	MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NVz0ZWJuOC13MECgcm0>	M3jLTFczKGh?	M{DkRWROW09?	M4LiRoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M1;nTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
SU-DHL-5	NXfveFB1S2WubDDWbYFjcWyrdImgRZN{[Xl?	NVrxfnNJOC13MECgcm0>	MXm3NkBp	MX3EUXNQ	MoG3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M2nEcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
SU-DHL-6	NHfvNnpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MnzCNE02ODBibl2=	MYC3NkBp	MXrEUXNQ	MkTh[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
SU-DHL-10	NFvRSolE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M1z4OFAuPTByIH7N	MXm3NkBp	Ml:ySG1UVw>?	MWrk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
RC-K8	MljtR4VtdCCYaXHibYxqfHliQYPzZZk>	NIfvZ44xNTVyMDDuUS=>	M{fBSFczKGh?	Ml:5SG1UVw>?	MX;k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MkPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEmyPVUoRjJ3MEC5Nlk2RC:jPh?=
OCI-Ly8	MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M2qybFAuPTByIH7N	MmLGO\|IhcA>?	MV3EUXNQ	Mlzj[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M4HWV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
OCL-Ly18	Mn\DR4VtdCCYaXHibYxqfHliQYPzZZk>	MX:wMVUxOCCwTR?=	MmDyO\|IhcA>?	M1zwbWROW09?	M1Tsd4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	Ml;BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEmyPVUoRjJ3MEC5Nlk2RC:jPh?=
OCI-Ly3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorlNVczNzJ3MD:1NFAhdk1?	MoHXNk84KGR?	MUTEUXNQ	NYi2R2pIcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC\|dXKtS\|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=>	NFvlbWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
OCI-Ly8	M4LL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF75S5AyPzJxMkWwM\|UxOCCwTR?=	MYSyM\|ch\A>?	M1vtNmROW09?	NWnObldRcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC\|dXKtS\|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=>	M3nObVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
SU-DHL-4	NUWwV4U4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17ucVE4Oi9{NUCvOVAxKG6P	NITYdGkzNzdiZB?=	NFjWcnRFVVOR	NEfuXohqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg	M{\JXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
SU-DHL-10	NIfhN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnsNVczNzJ3MD:1NFAhdk1?	MVuyM\|ch\A>?	MknpSG1UVw>?	MorwbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW\|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?=	NH\6V5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
OCI-Ly3	MVjBdI9xfG:\|aYOgRZN{[Xl?	NEnnPGsyPzJxMkWwJI5O	MUm3[C=>	M4XxdGROW09?	NIi3NnlqdmO{ZXHz[ZMh[2G\|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk>	NVzydZJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
OCI-Ly8	Mn7uRZBweHSxc3nzJGF{e2G7	MnXQNVczNzJ3MDDuUS=>	NUDmdWVVP2R?	MW\EUXNQ	NE\wNmhqdmO{ZXHz[ZMh[2G\|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk>	MoX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEmyPVUoRjJ3MEC5Nlk2RC:jPh?=
SU-DHL-4	MmXNRZBweHSxc3nzJGF{e2G7	M3\QblE4Oi9{NUCgcm0>	M{PETldl	MWLEUXNQ	NIrQSYdqdmO{ZXHz[ZMh[2G\|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
SU-DHL-10	MVnBdI9xfG:\|aYOgRZN{[Xl?	MVSxO\|IwOjVyIH7N	M1vETFdl	MoTESG1UVw>?	MVHpcoNz\WG\|ZYOgZ4F{eGG\|ZT2zM\|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm=	NVzK[ZdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
Rosetta2 DE3	M2ewUmZ2dmO2aX;uJIF{e2G7				NHPrOmRM\CB;IECuNFA3OiEQvF2=	NYjwOZNYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NVrBdYVmTmy3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeR?=		M3O3[lMxKG2rboO=		NEfNbWVMcSB;IECuNFA3PiEQvF2=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	MoPFSpVv[3Srb36gZZN{[Xl?				MVXL[EA:KDBwMEC2O{DPxE1?	M3;6VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	M4mzW2ZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[Xl?		MX6zNEBucW6\|		MXjLbUA:KDBwMEC3OkDPxE1?	NH\pcVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3	NHK4fYpHdHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7		MXqzNEBucW6\|		NVfmfGN3U2liPTCwMlAxQDlizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	NHHUPIlHdHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7		MXGzNEBucW6\|		MXTLbUA:KDBwMEGwO{DPxE1?	NGfk[2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3	M1zDN2Z2dmO2aX;uJIF{e2G7				MmDDT4QhRSByLkCxNVch\|ryP	M3LpZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
MV4-11	NFfTNVBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M360c\|czKGh?		M2f5SmlEPTBiPTCwMlAyOiEQvF2=	NG\sWFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkezNVQ6OCd-Mk[3N\|E1QTB:L3G+
Rosetta2 DE3	M{C2b2ZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[Xl?		M4DkVFMxKG2rboO=		NXe5b41[U2liPTCwMlAyOiEQvF2=	M1;WSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
VCaP	M4nJb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NGG5eYIyOiCq		NH;hXoxKSzVyIE2gNE4xOTJizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
Rosetta2 DE3	MV\GcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHHzd4F6		NH\oR\|M{OCCvaX7z		M1rlfmtqKD1iMD6wNVI2KM7:TR?=	MoTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	MWrGeY5kfGmxbjDhd5NigQ>?				NHHscINM\CB;IECuNFEzQCEQvF2=	M3nsd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	M3m2OGZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[Xl?		MoTGN\|AhdWmwcx?=		NXLLd2dQU2liPTCwMlAyOzJizszN	NV\qdoF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NVOxempZTnWwY4Tpc44h[XO\|YYm=				MkfiT4QhRSByLkCxN\|Yh\|ryP	M4XpOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	MVHGeY5kfGmxbjDhd5NigQ>?				MW\L[EA:KDBwMEG0O{DPxE1?	MoXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	Mnq2Sox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDhd5NigQ>?		NVnaUopEOzBibXnudy=>		NYnCU25xU2liPTCwMlAyPDlizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
TY82	MlLORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MoHsO\|IhcA>?		MV7JR\|UxKD1iMD6wNVgh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV6NkexPEc,Ojh3OE[3NVg9N2F-
MM1S	M2G3T2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWi3NkBp		NXPtVW84UUN3MDC9JFAvODF7IN88US=>	NVTzeYw2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1PFY4OThpPkK4OVg3PzF6PD;hQi=>
MM1S	NGi3c3ZEgXSxdH;4bYNqfHliYYPzZZk>		MoSyO\|IhcA>?		NV\icG5ZUUN3MDC9JFAvODJizszN	MoCyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
HT-29	NHPsSVBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MkPqNVIhcA>?		M2PkfWlEPTBiPTCwMlAzKM7:TR?=	NF;IeFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWzOVA1PSd-Mki1N\|UxPDV:L3G+
MV4-11	NXyyT4JCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGnX[3A4OiCq		Mn;aTWM2OCB;IECuNFI{KM7:TR?=	MnS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUm0NlgoRjJ3NUW5OFI5RC:jPh?=
MV4-11	MVnDfZRwfG:6aXPpeJkh[XO\|YYm=		MojjOEBl[Xm\|		MnmzTWM2OCB;IECuNFI1KM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
MV4-11	NWDIPJZCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1PEVVQh\GG7cx?=		NFfaT3VKSzVyIE2gNE4xOjRizszN	MoDOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	NYm0eVlDTnWwY4Tpc44h[XO\|YYm=		NITRO3o{OCCvaX7z		Mm[2TWM2OCB;IECuNFI5PyEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
NALM16	NYWzUFJkS3m2b4TvfIlkcXS7IHHzd4F6		NILCN2Q2KGSjeYO=		NXPQNYdiTUN3MDC9JFAvODNizszN	MlrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{CwNlQoRjJ7MUewNFI1RC:jPh?=
BL21(DE3)-R3-pRARE2	NImyW4VHfW6ldHnvckBie3OjeR?=		MVyzNEBucW6\|		MleyTWM2OCB;IECuNFM{KM7:TR?=	NV;GWHZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixPVU4OjNpPkK4NVk2PzJ\|PD;hQi=>
BL21(DE3)	NWPYfVFSTnWwY4Tpc44h[XO\|YYm=				NXXPRpFNU2RiPTCwMlA{PCEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd\|MUS5NEc,OjZ5M{G0PVA9N2F-
Rosetta2 DE3	NXOxZYE1Tmy3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeR?=		MnzsN\|AhdWmwcx?=		MUHJR\|UxKD1iMD6wN\|U4KM7:TR?=	NYP4T2JYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NELme2ZHdHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7		M33u[\|MxKG2rboO=		MVnJR\|UxKD1iMD6wOFIzKM7:TR?=	M4PJXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NE[zOFg4Lz5{OES2N\|Q5PzxxYU6=
Rosetta2 DE3	MlrrSox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDhd5NigQ>?		NVzwdGdnOzBibXnudy=>		NVTKclBUUUN3MDC9JFAvODR4NzFOwG0>	M2TYbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NE[zOFg4Lz5{OES2N\|Q5PzxxYU6=
MOLM13	NXzURXpJS3m2b4TvfIlkcXS7IHHzd4F6		M4fUZlQh\GG7cx?=		MUnJR\|UxKD1iMD6wOVYh\|ryP	MnfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkO0PFcoRjJ6NE[zOFg4RC:jPh?=
MOLM13	Ml3US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmDOOEBl[Xm\|		NHL2OoJKSzVyIE2gNE4xPTZizszN	NHi4W449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
HL60	NI\kN2pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MU[3NkBp		MojwTWM2OCB;IECuNFYh\|ryP	NXXu[XVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO\|AxOjRpPkK5NVcxODJ2PD;hQi=>
HL60	M3PnU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NW\LVFFCOyCmYYnz		NX7qcFQ2T0N3MDC9JFAvODZizszN	M4nxb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkW3NFk6Lz5{OU[1O\|A6QTxxYU6=
NALM6	NHPkU3BEgXSxdH;4bYNqfHliYYPzZZk>		MWW1JIRigXN?		M2T4XmVEPTBiPTCwMlA3KM7:TR?=	M37ocFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUS5PFg6Lz5{OEW0PVg5QTxxYU6=
Raji	NWXYbnA4TnWwY4Tpc44h[XO\|YYm=				MULJR\|UxKD1iMD6wOkDPxE1?	MofxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5M{G0PVAoRjJ4N{OxOFkxRC:jPh?=
Raji	MWHGeY5kfGmxbjDhd5NigQ>?		NFjVdo41KGh?		MXTJR\|UxKD1iMD6wOlkh\|ryP	NXL6V5VHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4PThpPkK0PVAxPzV6PD;hQi=>
MM1S	NXPG[Fl[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NWLXVnNTPzJiaB?=		MmC5TWM2OCB;IECuNFY6OSEQvF2=	MmjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MkW0N\|UoRjJ7NUK1OFM2RC:jPh?=
BL21 (DE3)-codon plus-RIL	NXHEdXJJTmy3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeR?=		M{\DU4J6KG[udX;y[ZNk\W6lZTDhcol{d3S{b4D5JIF{e2G7		Mly2TWM2OCB;IECuNFch\|ryP	NY\UbFA1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1PFY4OThpPkK4OVg3PzF6PD;hQi=>
22Rv1	MlHtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MoHxPVYhcA>?		MYHJR\|UxKD1iMD6wO\|Eh\|ryP	MnHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
22Rv1	Mo[5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M2\BPVEzKGh?		NWnWT2tYUUN3MDC9JFAvODdzIN88US=>	NWTYTo4{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFE{PzFpPkK5OVQyOzdzPD;hQi=>
MV4-11	MmTGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?				MmHoTWM2OCB;IECuNFczKM7:TR?=	NIDLOWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG5OVczOyd-MkixPVU4OjN:L3G+
BL21(DE3)-R3-pRARE2	NVT5TXFxTnWwY4Tpc44h[XO\|YYm=		NXX2XG8yOzBibXnudy=>		M37oNWlEPTBiPTCwMlA4PyEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd\|MUS5NEc,OjZ5M{G0PVA9N2F-
BL21(DE3)-R3-pRARE2	Mmf4SpVv[3Srb36gZZN{[Xl?		M1nHNVMxKG2rboO=		MkDqTWM2OCB;IECuNFc4KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF7NUeyN{c,OjhzOUW3NlM9N2F-
BL21(DE3)-R3-pRARE2	NEHUXZpHfW6ldHnvckBie3OjeR?=		NIfIfJQ{OCCvaX7z		MULJR\|UxKD1iMD6wO\|ch\|ryP	NYW3cmZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|Y5OzRpPkK5O\|c3QDN2PD;hQi=>
MV4-11	MoLKR5l1d3SxeHnjbZR6KGG\|c3H5		NYjxdWJMOjRiaB?=		NHq0VG9IUTVyIE2gNE4xQCEQvF2=	NVHxN3ZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xPVE{PjNpPkK2NVkyOzZ\|PD;hQi=>
MV411	M4XkZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M3PWeFczKGh?		NUDIUYc3UUN3MDC9JFAvODhizszN	NGnMUJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOFUyOyd-MkizNVQ2OTN:L3G+
TY82	NFPqXZJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NHnINYM4OiCq		MUPJR\|UxKD1iMD6wPFA5KM7:TR?=	NXHaWpp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NlU1OzVpPkK5OVI2PDN3PD;hQi=>
HL60	M1zKcmZ2dmO2aX;uJIF{e2G7		NY\oXFNWOjRiaB?=		NGfjVGhKSzVyIE2gNE4xQDZizszN	NWXvd2NCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OFk5QDlpPkK4OVQ6QDh7PD;hQi=>
697	Mn;tR5l1d3SxeHnjbZR6KGG\|c3H5		NUHBWW5xPSCmYYnz		MUnFR\|UxKD1iMD6wPUDPxE1?	MmfrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{CwNlQoRjJ7MUewNFI1RC:jPh?=
Loucy	MYXDfZRwfG:6aXPpeJkh[XO\|YYm=		MmLNOUBl[Xm\|		MoLCSWM2OCB;IECuNFkh\|ryP	M{jxVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUewNFI1Lz5{OUG3NFAzPDxxYU6=
BL21(DE3)	NFjYTo5HfW6ldHnvckBie3OjeR?=				MXjL[EA:KDBwMEmyJO69VQ>?	M132S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|cyLz5{OUW0NVM4OTxxYU6=
BL21(DE3)-R3-pRARE2	NYThdFMxTnWwY4Tpc44h[XO\|YYm=				MnHLT4QhRSByLkGg{txO	MlS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3OUWwNFcoRjJ6NUm1NFA4RC:jPh?=
HT-29	NWjNUno5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkPvO\|IhcA>?		MWPJR\|UxKD1iMD6xNFQh\|ryP	Mmm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUm0NlgoRjJ3NUW5OFI5RC:jPh?=
MM1S	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1vXRlczKGh?		M4TsbWlEPTBiPTCwMlExQSEQvF2=	NELXbJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1PVQzQCd-MkW1OVk1Ojh:L3G+
LNCAP cells	M2HqcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				M2fpcGlEPTBiPTCwMlExQTZizszN	M2LuZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
T cells	MmXuSpVv[3Srb36gZZN{[Xl?		MXeyOEBp		NWDncItGUUN3MDC9JFAvOTFizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNEWxN{c,Ojh\|MUS1NVM9N2F-
HL60	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NGDKe4M4OiCq		NYXJTIU5UUN3MDC9JFAvOTFizszN	M4nwOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OE[5NVk1Lz5{Nki2PVE6PDxxYU6=
BL21(DE3)	MmrCSpVv[3Srb36gZZN{[Xl?				M163WWlEPTBiPTCwMlEzKM7:TR?=	MnT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5M{G0PVAoRjJ4N{OxOFkxRC:jPh?=
BL21(DE3)	MoXjSpVv[3Srb36gZZN{[Xl?		NYq1XIJmOi53IHi=		NIHoUnhKSzVyIE2gNE4yOiEQvF2=	NFPSbY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM4OSd-Mkm1OFE{PzF:L3G+
H1299	MmTSSpVv[3Srb36gZZN{[Xl?		MXqyOEBp		NUjh[Zd5TUN3MDC9JFAvOTV\|IN88US=>	NF3aUmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm0PVUzOSd-Mki5OFk2OjF:L3G+
HD-MB03	NVPEXXh2S3m2b4TvfIlkcXS7IHHzd4F6		MljjOUBl[Xm\|		NXrsXpJyTUN3MDC9JFAvOTZizszN	MnTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
LNCAP	MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NVPke2NJQTZiaB?=		NWf1coRsUUN3MDC9JFAvOTZizszN	M{HFOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
Hs578T	NEDp[3NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NWroPWdOOTJiaB?=		NV\Zblh{UUN3MDC9JFAvOTZizszN	NGjkSWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe1PFUyQCd-Mkm3OVg2OTh:L3G+
MV4-11	Moe1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NFXQZlYyOiCq		M131fmlEPTBiPTCwMlE3KM7:TR?=	MoTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{CwNlQoRjJ7MUewNFI1RC:jPh?=
LNCAP	NHn2XppCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MmTxNVIhcA>?		MWfJR\|UxKD1iMD6xOkDPxE1?	M33CUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|cyLz5{OUW0NVM4OTxxYU6=
C4-2B	NFjPbodCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MkDpPVYhcA>?		NX3veXFuUUN3MDC9JFAvOTlizszN	M4nxUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
C4-2B	NX7zV\|k3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M{fCTFEzKGh?		M3vEXGlEPTBiPTCwMlE6KM7:TR?=	NHe3b2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM4OSd-Mkm1OFE{PzF:L3G+
Vero E6	NXf3dGw{SW62aY\pdoFtKGGldHn2bZR6KGG\|c3H5		NEnW[XE1QCCq		MWDJR\|UxKD1iMD6xPVI4PSEQvF2=	MlHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzJ\|NUO4OVkoRjN{M{WzPFU6RC:jPh?=
MCF7	NFvleXFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M2f6blEzKGh?		NFXRN2xKSzVyIE2gNE4zKM7:TR?=	NWfBUW5QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
MV4-11	M4jrXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				MlLTTWM2OCB;IECuNlQh\|ryP	M2DkcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUSyO\|UyLz5{N{G0Nlc2OTxxYU6=
MV4-11	MUXDfZRwfG:6aXPpeJkh[XO\|YYm=		NYfYcGdIPzJiaB?=		Mn60TWM2OCB;IECuNlQzKM7:TR?=	NVLk[HY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVcxOTFpPkKzOVE4ODFzPD;hQi=>
MX1	MmPqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MX:3NkBp		M13HR2VEPTBiPTCwMlI2PCEQvF2=	M4XMUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUS5OVIyLz5{OEm0PVUzOTxxYU6=
HT-29	M2XlcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MV:3NkBp		M3zsfWlEPTBiPTCwMlI5KM7:TR?=	Mlj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5M{G0PVAoRjJ4N{OxOFkxRC:jPh?=
HFL1	NIPaO2lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MUSxNkBp		MVTJR\|UxKD1iMD6yPUDPxE1?	NUOycW52RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
MDA-MB-231	M{nyXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVWzJIRigXN?		NEDwfXNISzVyIE2gNE4{KM7:TR?=	NX3NUXVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OFk5QDlpPkK4OVQ6QDh7PD;hQi=>
MV4-11	NH72U29CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MVu0PEBp		MYrFR\|UxKD1iMD6zN\|EyOyEQvF2=	NF6wd2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW5OVAxPyd-Mki1PVUxODd:L3G+
K562	NVHuUldESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=				NVj3Rm06UUN3MDC9JFAvPjRizszN	MknoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzNEK3OVEoRjJ5MUSyO\|UyRC:jPh?=
HL60	NEm5fYNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MlfkOFghcA>?		NEX0OZNGSzVyIE2gNE44PDF\|MTFOwG0>	NWTHWIRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1PVUxODdpPkK4OVk2ODB5PD;hQi=>
NCI-H1975	MlPrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NHn5SpAyOiCq		NFizW3RKSzVyIE2gNU4zOyEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
SAE	M1HhUmZ2dmO2aX;uJIF{e2G7		M{P5OFQhcA>?		NIqzZ2JKSzVyIE2gNU4{QCEQvF2=	NYK3dHNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OFk4PDFpPkK5OlQ6PzRzPD;hQi=>
SAE	MlzUSpVv[3Srb36gZZN{[Xl?		NH3DZYU1KGh?		M3zIZWlEPTBiPTCxMlQ6KM7:TR?=	Mm\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NEm3OFEoRjJ7NkS5O\|QyRC:jPh?=
SAE	NWTZfVJyTnWwY4Tpc44h[XO\|YYm=		MojpOEBp		MXnJR\|UxKD1iMT61NUDPxE1?	NEiy[HI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[0PVc1OSd-Mkm2OFk4PDF:L3G+
U2OS	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MYqxNkBp		NIDreFRKSzVyIE2gNU43OiEQvF2=	Mn\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
SAE	M3;kXWZ2dmO2aX;uJIF{e2G7		MYi0JIg>		MXjJR\|UxKD1iMT62N{DPxE1?	NFjDWHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[0PVc1OSd-Mkm2OFk4PDF:L3G+
A549	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MlrvNVIhcA>?		NIrscIVKSzVyIE2gNU43PyEQvF2=	NGS2NpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe1PFUyQCd-Mkm3OVg2OTh:L3G+
MCF7	NUHaN5dYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2XXUFMh\GG7cx?=		M{fzeWdEPTBiPTCxMlch\|ryP	NF3Udm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW0PVg5QSd-Mki1OFk5QDl:L3G+
DU145	NXf5cGV{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MlPsPVYhcA>?		MlTzTWM2OCB;IEKuOVIh\|ryP	MlrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
DU145	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NGXHb3oyOiCq		NEXydm1KSzVyIE2gNk42OiEQvF2=	NH\xSok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM4OSd-Mkm1OFE{PzF:L3G+
T47D	M1XJOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUmzJIRigXN?		Mn;5S2M2OCB;IEKuPEDPxE1?	M4XlblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUS5PFg6Lz5{OEW0PVg5QTxxYU6=
PC3	NYjrUHdFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NG[3O\|M6PiCq		MnLXTWM2OCB;IEOuNFEh\|ryP	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
PC3	M2jGc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M3HMeFEzKGh?		M{XqOWlEPTBiPTCzMlAyKM7:TR?=	MmW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzO\|EoRjJ7NUSxN\|cyRC:jPh?=
HeLa	MmL6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MlLuNVIhcA>?		NYTONVNQUUN3MDC9JFMvPzZizszN	M4fWbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
K562	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmTEN{Bl[Xm\|		NV\Kc2F1T0N3MDC9JFMvQCEQvF2=	NXvtenJSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OFk5QDlpPkK4OVQ6QDh7PD;hQi=>
A2780	NF3wTo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml\qN{Bl[Xm\|		NWrF[nF[T0N3MDC9JFQh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV2OUi4PUc,Ojh3NEm4PFk9N2F-
HL60	M2nNPWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NV;HWI1OOjRiaB?=		NHLqTFVKSzVyIE2gOU4{KM7:TR?=	Ml22QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd{Nk[5PVkoRjJ5Mk[2PVk6RC:jPh?=
MV4-11	MVfDfZRwfG:6aXPpeJkh[XO\|YYm=		MYiyOEBp		MV3JR\|UxKD1iNj60JO69VQ>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJ4Nkm5PUc,Ojd{Nk[5PVk9N2F-
K562	M4LocWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MXS3NkBp		NHXUbJpKSzVyIE2gPU4yOiEQvF2=	NUDLcIVjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVQ2OTNpPkK4N\|E1PTF\|PD;hQi=>
OVCAR5	NVTnfFZTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlfrN{Bl[Xm\|		NGrYTYJISzVyIE2gNVIh\|ryP	NVW3bmRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OFk5QDlpPkK4OVQ6QDh7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; PubMed: 26119999 Chem Biol The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. c-Myc; PubMed: 23792448 Oncogene PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. p27; PubMed: 23792448 Oncogene Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.	26119999 23792448
Growth inhibition assay	Cell viability; PubMed: 23792448 Oncogene PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control.	23792448
Immunofluorescence	GM130; PubMed: 29074567 Mol Biol Cell Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. MHC / EdU; PubMed: 28733670 Sci Rep C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.	29074567 28733670

In vivo

(+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. ^[1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. ^[2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. ^[3]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: MC 11060 cells
Concentrations: ~500 nM
Incubation Time: 48 hours
Method:
Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: Mice bearing NMC 797 xenografts
Dosages: 50 mg/kg
Administration: intraperitoneal injection
(Only for Reference)

References

[4] Li Z, et al. Nucleic Acids Res, 2013, 41(1), 277-287.

- Collapse

Solubility (25°C)

In vitro	DMSO	91 mg/mL warmed (199.12 mM)
	Water	Insoluble
	Ethanol	'91 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download (+)-JQ1 SDF

Molecular Weight	456.99
Formula	C₂₃H₂₅ClN₄O₂S
CAS No.	1268524-70-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can I reconstitute the compound for in vivo injection?
Answer:
JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Target Protein Ligand Inhibitors with Unique Features

BET Inhibitor in Clinical Trial

RVX-208 ^New : Phase II for Dyslipidemia.
Newest BET Inhibitor

I-BET-762 : Inhibitor for BET proteins with IC50 of ~35 nM, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins.

Choose Your Country or Region

By Signaling Pathways

By product type

(+)-JQ1